Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.
about
Chemotherapy and radiotherapy for inoperable advanced pancreatic cancerChemotherapy and radiotherapy for inoperable advanced pancreatic cancerTargeted Therapy in Biliary Tract CancersAdvances in systemic therapy for advanced pancreatobiliary malignanciesMetastatic pancreatic cancer: Is there a light at the end of the tunnel?A phase II trial of marimastat in advanced pancreatic cancerIdentification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decadesGemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trialsAlternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients.Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data.Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma.Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.Gemcitabine in combination with EGF-Receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: a case report.Technology insight: Photodynamic therapy for cholangiocarcinoma.Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic adenocarcinoma.Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial.The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma.Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.Fixed dose-rate infusion of gemcitabine in combination with cisplatin and UFT in advanced carcinoma of the pancreas.Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer.EGFR expression in gallbladder carcinoma in North America.Combined chemotherapy of irinotecan and low-dose cisplatin (I/low-P) against metastatic biliary tract cancer.Phase II study of 5-fluorouracil and paclitaxel in patients with gemcitabine-refractory pancreatic cancer.Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study.Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers.Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer.Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 StudyGemcitabine versus gemcitabine combined with cisplatin treatment locally advanced or metastatic pancreatic cancer: a retrospective analysis.The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.Gemcitabine with carboplatin for advanced biliary tract cancers: a phase II single institution study.Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective studyEfficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients.Outcome of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) chemotherapy and analysis of prognostic factors in patients with refractory advanced biliary tract cancer.Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy
P2860
Q24240739-6AFFB83D-3971-4580-A5B2-D3A02B7EFFACQ24245085-D2D1659A-81E4-45CA-A67D-46F64C75D066Q26798443-4CD1265C-A350-4A77-82EC-8E7CAB12D3C5Q26822703-D1693825-266E-4F18-B060-345A7C75788BQ28082919-F3393F51-CFC9-44E7-AE48-44EB225388E8Q28366568-DB7732D1-677A-47B9-B022-40E725D2EC58Q30300756-63011F8D-2ED1-4C83-9BFE-94CDDF7FE533Q30318857-78BD3DA7-9B71-46AA-97C7-88ACD0ABAF6FQ30665974-277A761C-ADB0-44C9-9E36-3A94A8444ED0Q31033443-9FA9BC24-A419-4ED5-BCA7-E0F3C583C5F0Q33212427-CD400931-4857-4CFE-9878-65357D66DB04Q33214444-C8A78F37-948F-49DB-9734-7B97E614837AQ33250432-331A0C01-5025-4CA8-933B-6AA35359658EQ33252543-68FDFA33-C306-4983-B73F-D1423940588AQ33327923-86FB2E0F-C009-4D92-99F2-6468A43C2957Q33357700-E811F626-EFFE-4A57-A4C9-81A44A04B556Q33364008-D12776FA-2F77-412B-9521-0E7E6835A09CQ33365804-257F368F-09C4-4690-93FB-A165D2F76AF7Q33366682-760B1A22-B2E6-47A7-B029-B956A13A9903Q33367224-1BD6A516-93C2-4385-BA06-F7897B3A4A30Q33369849-11E51623-8E69-46BC-8522-ED8A126C68EEQ33370390-CCD69EB6-6C9D-4F99-A259-6A08239841F4Q33371306-741BFC7B-4478-4885-ABEF-89647CE5532BQ33372792-73D82AC7-5F3B-47A1-90CA-60F9496A60E6Q33372825-8E68C1EB-C170-4BA2-A2CB-CEFE3E67D734Q33381016-E803A8EE-618F-4BCB-94E2-B24AF5008035Q33383423-9A5FB2AC-883D-4D7A-9BF3-D13F1A74729EQ33384257-82F28C2E-6B84-4D9C-B4AE-E7CC6FE65D76Q33384513-951E24B1-4361-4F26-BC6E-FD365F44805DQ33385243-E09C1AD6-826B-4CF7-9079-E8A149BA66EDQ33385654-58AAFD49-6AEC-47F6-AEEB-0A95F3401BBFQ33385766-2F1EB3F1-987C-4916-B7CF-3F42BAD4D98DQ33385864-A0C96F90-364B-419B-BF3D-5F091F3490BDQ33388402-2BCEEE66-6FED-4D02-9031-AD4E37342792Q33391003-D7152DA8-E666-425C-ABFB-6712F381F0A8Q33394065-A9F9B8BA-C2E0-49AF-8347-52F800BCAE82Q33394190-D7856C50-5247-4E21-AE1D-3D3523B5BA01Q33399656-86739FE1-5AC7-422A-854A-30556B1ECB84Q33402129-0D4DD8F3-2F66-4AE2-AF36-77345FBB7957Q33417019-BDFEC489-3A11-41CC-A8F2-77B161CA0218
P2860
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer.
description
1996 nî lūn-bûn
@nan
1996 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Chemotherapy improves survival ...... pancreatic and biliary cancer.
@ast
Chemotherapy improves survival ...... pancreatic and biliary cancer.
@en
Chemotherapy improves survival ...... pancreatic and biliary cancer.
@nl
type
label
Chemotherapy improves survival ...... pancreatic and biliary cancer.
@ast
Chemotherapy improves survival ...... pancreatic and biliary cancer.
@en
Chemotherapy improves survival ...... pancreatic and biliary cancer.
@nl
prefLabel
Chemotherapy improves survival ...... pancreatic and biliary cancer.
@ast
Chemotherapy improves survival ...... pancreatic and biliary cancer.
@en
Chemotherapy improves survival ...... pancreatic and biliary cancer.
@nl
P2093
P1433
P1476
Chemotherapy improves survival ...... pancreatic and biliary cancer.
@en
P2093
C Svensson
G Jacobsson
H Sellström
L K Enander
P O Sjödén
P304
P356
10.1093/OXFORDJOURNALS.ANNONC.A010676
P577
1996-08-01T00:00:00Z